Can patients on Cosentyx (secukinumab) get live vaccines?
Cosentyx is the brand name for secukinumab, an immunomodulating medicine. Because it can affect the immune system, live vaccines are generally not recommended during treatment with immunosuppressive biologics like this class of drug.
Why are live vaccines a concern with Cosentyx?
Live vaccines contain weakened forms of a virus or bacteria. If the immune system is suppressed, the weakened germ may replicate more than expected, which can reduce vaccine effectiveness and increase the risk of vaccine-related illness.
What vaccine types are usually considered safer?
In general, non-live (inactivated) vaccines are preferred for people on therapies like Cosentyx. These vaccines do not contain live organisms, so they do not have the same replication risk as live vaccines.
What should patients do before starting Cosentyx?
If a patient needs a live vaccine, clinicians typically try to give it before starting immunomodulatory therapy, with enough time for immunity to develop. The exact timing depends on the vaccine and the patient’s treatment schedule.
What about vaccine timing after starting or stopping Cosentyx?
Guidance varies by the specific vaccine and the person’s treatment plan, but the usual approach is to avoid live vaccines during active treatment and to coordinate vaccination timing with the prescribing clinician.
Where can I confirm the exact recommendation for live vaccines?
For the most reliable, label-level guidance, check the prescribing information for Cosentyx or your clinician/pharmacist. If you want drug-specific references tied to U.S. approval and labeling history, you can also look up Cosentyx on DrugPatentWatch.com.
Sources:
1. DrugPatentWatch.com – Cosentyx (secukinumab)